Dr.ย Rui-Huaย Xu
MD, MSc (Oncology), PhD (Oncology)
Professor of Medical Oncology & President
corporate_fareSun Yat-sen University Cancer Center, Guangzhou
Rui-Hua Xu
MD, MSc (Oncology), PhD (Oncology)
Prof. Rui-Hua Xu is one of China's foremost gastrointestinal medical oncologists, currently serving as Professor of Medical Oncology and President of Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou. He also directs the State Key Laboratory of Oncology in South China and serves as Chairman of the Chinese Society of Clinical Oncology.
With more than three decades of academic and clinical work, Prof. Xu has built an internationally recognised programme in GI cancer treatment and translational research. His clinical focus covers colorectal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal squamous cell carcinoma, with particular emphasis on advanced and metastatic disease. He has been a leading investigator in global and domestic multi-centre clinical trials evaluating immunotherapy combinations for GI cancers, including the landmark ESCORT-1st study published in JAMA. His research interests include PD-1 checkpoint inhibitor strategies, liquid biopsy using circulating tumour DNA, biomarker-guided treatment selection, cancer drug resistance, and mechanisms of metastasis. Prof. Xu has been recognised as a Clarivate Highly Cited Researcher and was elected Academician of the Chinese Academy of Engineering in 2025.
CancerFax can coordinate medical report review and consultation support for international patients seeking an expert opinion from Prof. Rui-Hua Xu, subject to hospital availability and case acceptance.
Why Consider Prof. Rui-Hua Xu?
Prof. Xu brings together world-class clinical expertise in gastrointestinal oncology, prolific translational research, and national academic leadership in one of China's premier cancer institutions.
Areas of Specialisation
Gastrointestinal cancer medical oncology, immunotherapy strategies, and precision diagnosis
Prof. Xu specialises in the medical oncology of digestive tract cancers, with expertise spanning systemic treatment, immunotherapy, targeted therapy, and translational research for advanced and metastatic disease.
Gastrointestinal Cancer Oncology
Comprehensive medical oncology for cancers of the colon, rectum, stomach, gastroesophageal junction, and oesophagus, including advanced and metastatic presentations.
- arrow_rightMedical oncology for early, locally advanced, and metastatic colorectal cancer
- arrow_rightBiomarker-guided systemic therapy selection
- arrow_rightCombination immunotherapy for selected MSS/pMMR colorectal cancer (phase 2 research)
- arrow_rightFirst- and second-line systemic treatment planning for gastric and GEJ adenocarcinoma
- arrow_rightImmunotherapy combinations including PD-1 inhibitor-based regimens
- arrow_rightParticipation in RATIONALE-305 phase 3 trial (tislelizumab plus chemotherapy)
- arrow_rightMedical oncology for esophageal squamous cell carcinoma
- arrow_rightImmunotherapy combination strategies for advanced or metastatic disease
- arrow_rightLead author in ESCORT-1st trial (camrelizumab plus chemotherapy, JAMA 2021)
Immunotherapy & Precision Oncology
Advanced systemic approaches for GI cancers including checkpoint inhibitor therapy, biomarker profiling, and ctDNA-based diagnostic strategies.
- arrow_rightPD-1 and PD-L1 inhibitor-based treatment strategies for GI cancers
- arrow_rightCombination immunotherapy and chemotherapy protocols
- arrow_rightTreatment planning informed by tumour microenvironment and biomarker analysis
- arrow_rightCirculating tumour DNA testing for early diagnosis and treatment response assessment
- arrow_rightBiomarker-guided treatment selection for advanced GI cancers
- arrow_rightResearch into drug resistance mechanisms through molecular profiling
Procedures Performed
Systemic treatment, immunotherapy, and precision diagnostic services for GI cancers
Prof. Xu's clinical practice encompasses medical oncology for digestive tract cancers, with a focus on evidence-based systemic therapy, immunotherapy, targeted treatment, and translational diagnostic approaches.
Medical Oncology for GI Cancers
Medical OncologySystemic treatment planning and administration for colorectal, gastric, GEJ, and esophageal cancers at all disease stages.
Immunotherapy
Targeted TherapyPD-1 and PD-L1 checkpoint inhibitor-based treatment strategies, combination immunotherapy protocols, and novel immunotherapy regimens for eligible GI cancer patients.
Precision Diagnostics & Monitoring
MonitoringBiomarker-guided treatment selection, ctDNA liquid biopsy, and treatment response monitoring for GI cancers.
Second Opinion โ Advanced GI Cancer
Second OpinionExpert review of complex or advanced GI cancer cases, including metastatic colorectal cancer, gastric cancer, GEJ cancer, and esophageal squamous cell carcinoma.
Research & Publications
Peer-reviewed contributions and clinical trial leadership in gastrointestinal oncology
Prof. Xu has authored more than 200 peer-reviewed papers in leading international journals including JAMA, Cancer Cell, Nature Medicine, Nature Materials, and Lancet Oncology. His research spans GI cancer medical oncology, immunotherapy, liquid biopsy, biomarker discovery, drug resistance, and metastasis.
Prof. Xu's full publication list and clinical trial participation record is available on PubMed, ORCID (0000-0001-9771-8534), and the official Sun Yat-sen University Cancer Center website.
Education & Training
Prof. Xu completed his medical education and doctoral training entirely at leading Chinese institutions, progressing through an MD, a Master's degree in Oncology, and a PhD in Oncology at Sun Yat-sen University of Medical Sciences.
Clinical Experience
Prof. Xu has spent the majority of his career at Sun Yat-sen University Cancer Center, where he has risen to the position of Professor of Medical Oncology and President. He concurrently leads the State Key Laboratory of Oncology in South China and holds major national roles in oncology leadership.
Languages & International
Prof. Xu's verified consultation languages are not publicly specified in official sources. The following reflects general clinical context at SYSUCC.
CancerFax can coordinate professional medical interpreter support for international patients seeking consultation at Sun Yat-sen University Cancer Center.
CancerFax can coordinate professional medical interpreter support for international patients.
How CancerFax Helps You Access Dr. Rui-Hua Xu
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Rui-Hua Xu's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Rui-Hua Xu's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Rui-Hua Xu before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Rui-Hua Xu's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Rui-Hua Xu's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Rui-Hua Xu's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Rui-Hua Xu
Prof. Xu specialises in gastrointestinal cancers, including colorectal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal cancer. His academic specialty covers the medical treatment of digestive tract tumours, with particular focus on advanced and metastatic disease, immunotherapy combinations, and precision oncology approaches.
Prof. Xu is based at Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou, China, where he serves as Professor of Medical Oncology and President. He also directs the State Key Laboratory of Oncology in South China.
CancerFax can coordinate medical report review and consultation support for international patients seeking an expert opinion from Prof. Xu, subject to hospital availability and individual case acceptance. Please submit your medical records through CancerFax and the team will guide the next steps.
Submit your pathology reports, imaging, treatment history, and relevant test results through CancerFax. The CancerFax team will review the documents, prepare the case, and coordinate with Sun Yat-sen University Cancer Center on your behalf. The final consultation format and timeline depend on the hospital's scheduling and case acceptance.
Prof. Xu's research covers GI cancer medical oncology, immunotherapy for digestive tract cancers, PD-1 checkpoint inhibitor strategies, liquid biopsy and circulating tumour DNA, biomarker-guided treatment planning, cancer drug resistance, and metastasis mechanisms. He has published more than 200 peer-reviewed papers in journals including JAMA, Cancer Cell, Nature Medicine, and Lancet Oncology.
Yes. Prof. Xu has served as a leading principal investigator in global and domestic multi-centre GI cancer clinical trials. He was the senior author of the ESCORT-1st trial (JAMA, 2021), which evaluated camrelizumab plus chemotherapy in advanced esophageal squamous cell carcinoma, and contributed to the RATIONALE-305 phase 3 trial in gastric and GEJ cancer (BMJ, 2024). He has also contributed to phase 2 immunotherapy combination research in colorectal cancer (Nature Medicine, 2024).
Connect with Rui-Hua Xu Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.